Can 'Zombie Cell' drugs strengthen aging bones?
NCT ID NCT06018467
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether a combination of three drugs—dasatinib, quercetin, and nicotinamide riboside—can improve bone health in 120 adults aged 60-90 with osteopenia or osteoporosis. The goal is to see if these 'senolytic' drugs can clear aging cells from the skeleton and reduce bone loss. Participants take the drugs for a short period, and researchers measure changes in bone turnover markers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dasatinib, Quercetin, and Nicotinamide Riboside
- What this could lead to
- If successful, this could point toward a new way to treat osteoporosis by targeting aging cells in the bone, potentially reducing fracture risk.
- What could go wrong
- This is an early Phase 2 trial with only 120 participants, so results may not apply to everyone. The combination therapy may cause side effects or fail to improve bone health significantly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED BONE LOSS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Odense University Hospital
Odense, 5000, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.